CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set of leukemia patients. However, CAR T-cell therapy thus far has been largely restricted to targeting ...

(Nasdaq: MRNA), has announced promising pre-clinical results for their innovative anti-GPC3 chimeric antigen receptor macrophage (CAR-M) therapy targeting hepatocellular carcinoma (HCC).

The mRNA CAR-T modality collects T-cells from a patient using a personalized approach, and adds a CAR, or a chimeric antigen receptor, to the cell using mRNA. The company says in its 10-K that ...

Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful ...

Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product targeting B-cell maturation antigen (BCMA) in ...

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological malignancies, is presenting clinical data from a ...